Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced that it has entered into an asset purchase agreement with Matrivax ...
Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2026.
Novavax (NVAX) shares added ~6% in the premarket on Wednesday after the COVID-19 vaccine maker well exceeded Street forecasts with its Q1 financials, thanks to a licensing deal with Pfizer (PFE) ...
Total revenue of $140 million in the first quarter of 2026 Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious ...
Indian billionaire Dilip Shanghvi’s plans to expand his healthcare empire in the U.S., the hantavirus outbreak on a cruise ...
A new therapy that combines two existing drugs shows promise for patients with inflammatory bowel disease who have exhausted ...
Hosted on MSN
Living well with Crohn’s and colitis
Crohn’s disease and ulcerative colitis may share symptoms, but they affect different parts of the digestive tract and can require different treatments. Understanding these differences helps patients ...
Visiting any medical facility is nightmare fuel for millions of Americans, and a lurking bacteria threatens to strike the ...
Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease and ulcerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results